NCT07341776 Steroid Use in Treatment of Allergic Reactions to Food
| NCT ID | NCT07341776 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Johannes Trueck |
| Condition | Anaphylactic Reaction |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2026-01-26 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 160 participants in total. It began in 2026-01-26 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, the investigators want to find out whether a specific medication commonly used for severe allergic reactions is really necessary. When children have allergic reactions to foods, they are often given medications to relieve the symptoms. In addition to adrenaline and antihistamines, steroids are frequently administered in German-speaking Switzerland. However, it is unclear whether steroids are really helpful in this situation. To investigate this, the investigators are comparing two groups: one group receives additional steroids, and the other does not. Which treatment a participant receives is decided randomly, like flipping a coin. The study takes place during a pre-scheduled provocation test at the clinic. If an allergic reaction occurs, the usual emergency medications will be administered. Doctors will closely monitor how the reaction develops. No additional tests or visits are required. The results of this study could help improve allergy treatment in the future.
Eligibility Criteria
Inclusion Criteria: * suspected or confirmed IgE-mediated food allergy Exclusion Criteria: * Non-IgE mediated food allergies * Non-food allergies * Age outside the specified range * Contraindications for an oral food challenge or oral steroid use within one week before the challenge.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07341776 clinical trial?
This trial is open to participants of all sexes, aged 6 Months or older, up to 18 Years, studying Anaphylactic Reaction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07341776 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07341776 currently recruiting?
Yes, NCT07341776 is actively recruiting participants. Contact the research team at johannes.trueck@kispi.uzh.ch for enrollment information.
Where is the NCT07341776 trial being conducted?
This trial is being conducted at Basel, Switzerland, Zurich, Switzerland.
Who is sponsoring the NCT07341776 clinical trial?
NCT07341776 is sponsored by Johannes Trueck. The trial plans to enroll 160 participants.